Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

AVAH vs. CHE: Which Stock Is the Better Value Option?

Chemed Corporation recently reported past second-quarter 2026 results showing higher net income of US$67.7 million, with both basic and diluted EPS from continuing operations rising compared with a year earlier. Alongside these earnings, Chemed continued a long-running capital return program with additional buybacks and now has repurchased over US$2.91 billion of its shares since 2011, while facing renewed pressure from activist investor Barington Capital to review its strategy and...

Healthcare services company Chemed Corporation (NYSE:CHE) announced better-than-expected revenue in Q2 CY2026, with sales up 8.8% year on year to $673.3 million. Its non-GAAP profit of $6.06 per share was 8.2% above analysts’ consensus estimates.

Chemed Corp (CHE) reports robust cash flow and strategic acquisitions, despite facing lead generation and marketing cost challenges.

Chemed (NYSE:CHE) reported second-quarter 2026 results marked by stronger-than-expected performance at its VITAS hospice business, while Roto-Rooter delivered revenue growth but continued to face higher customer-acquisition costs. President and Chief Executive Officer Kevin McNamara said consolidat

Moby summary of Chemed Corporation's Q2 2026 earnings call

Chemed (CHE) delivered earnings and revenue surprises of +9.19% and +1.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare services company Chemed Corporation (NYSE:CHE) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 8.8% year on year to $673.3 million. Its non-GAAP profit of $6.06 per share was 8.2% above analysts’ consensus estimates.

Healthcare services company Chemed Corporation (NYSE:CHE) will be reporting earnings this Tuesday after market close. Here’s what to look for.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.7% gain over the past six months, beating the S&P 500 by 1.8 percentage points.

Chemed trades at $513.71 and has moved in lockstep with the market. Its shares have returned 13.3% over the last six months while the S&P 500 has gained 8.4%.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.